admin – Page 4462 – Get News Story

Gastroesophageal Reflux Disease Market Expected to rise, 2034 | ddpharma, Arog Pharmaceuticals, Chong Kun Dang Pharmaceutical, Cinclus Pharma, Cogent Biosciences, Daewoong Pharmaceutical, HK inno

“Gastroesophageal Reflux Disease market”

The Gastroesophageal Reflux Disease market growth is driven by factors like increase in the prevalence of Gastroesophageal Reflux Disease, investments in research and development, entry of emerging therapies during the study period 2020-2034.

The Gastroesophageal Reflux Disease market report also offers comprehensive insights into the Gastroesophageal Reflux Disease market size, share, Gastroesophageal Reflux Disease epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Gastroesophageal Reflux Disease market size growth forward.

Some of the key highlights from the Gastroesophageal Reflux Disease Market Insights Report:

Several key pharmaceutical companies, including ddpharma, Arog Pharmaceuticals, Chong Kun Dang Pharmaceutical, Cinclus Pharma, Cogent Biosciences, Daewoong Pharmaceutical, HK inno.N Corporation, Jeil Pharmaceutical, Onconic Therapeutics, Plexxikon, Renexxion, Taiho Pharmaceutical, Takeda, Trio Medicines, and others, are developing novel products to improve the Gastroesophageal Reflux Disease treatment outlook.
In July 2024, Phathom Pharmaceuticals obtained an expanded indication for its acid suppression medication. The FDA approved the inclusion of heartburn relief associated with non-erosive gastroesophageal reflux disease in Voquezna’s label.
In November 2023, the FDA approved VOQUEZNA (vonoprazan) tablets in 10 mg and 20 mg dosages, a pioneering potassium-competitive acid blocker (PCAB), as a new treatment option for adults. This medication is indicated for healing all grades of Erosive Esophagitis, also known as Erosive GERD, as well as for maintaining healing and relieving heartburn associated with Erosive GERD.
In May 2023, Phathom Pharmaceuticals resubmitted its New Drug Application to the FDA for vonoprazan, seeking approval for the treatment of erosive gastroesophageal reflux disease (GERD), also known as erosive esophagitis.
In June 2022, Zydus Lifesciences received FDA approval to market Famotidine tablets in 20mg and 40mg strengths. Famotidine, a histamine H2 receptor blocker, works by reducing stomach acid and is used to relieve and prevent heartburn and other symptoms of acid reflux.
Several pharmaceutical companies, including Cinclus Pharma, Braintree (part of Sebela Pharmaceuticals), and N-Zyme Biomedical Inc., are actively researching and developing new therapies to meet the unmet needs of GERD patients.
As per DelveInsight analysis, the Gastroesophageal Reflux Disease market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Gastroesophageal Reflux Disease Market Landscape

Gastroesophageal Reflux Disease Overview

Gastroesophageal reflux disease (GERD) is a chronic condition in which stomach contents, including acid and bile, flow back into the esophagus, causing symptoms like heartburn, regurgitation, and chest pain. It commonly results from a dysfunction of the lower esophageal sphincter (LES), which typically prevents gastric contents from entering the esophagus. Contributing factors include hiatal hernia, poor esophageal motility, obesity, and certain dietary habits, such as consuming spicy or fatty foods, caffeine, and alcohol. GERD can present as non-erosive reflux disease (NERD), where no visible damage occurs to the esophageal lining, or as erosive esophagitis, which involves inflammation and damage to the esophageal tissue.

Symptoms of GERD can vary in intensity and may include heartburn (a burning sensation in the chest, often aggravated by eating or lying down), regurgitation of acid into the mouth, difficulty swallowing (dysphagia), chest pain, and chronic cough. These symptoms can negatively affect quality of life and may lead to complications such as esophageal strictures, Barrett’s esophagus, and esophageal adenocarcinoma if not treated.

Do you know the treatment paradigms for different countries? Download our Gastroesophageal Reflux Disease Market Sample Report

Gastroesophageal Reflux Disease Epidemiology Insights

Our analysis shows that the prevalence of GERD in North America ranges from 18% to 28%, while in Europe, it varies from 9% to 26%, indicating a considerable disease burden across both regions.
We also found that females have a higher prevalence of GERD compared to males, suggesting a gender disparity in the occurrence of the condition. This highlights the importance of addressing gender-specific factors in GERD management and treatment. The higher prevalence in females may be due to factors such as hormonal changes, differences in esophageal motility, and anatomical differences.
Additionally, our findings indicate that the age group of 50-59 years has the highest prevalence of GERD, while those aged 70 and above have the lowest. This trend could be linked to age-related changes in gastrointestinal function, lifestyle factors, and the presence of comorbidities in older individuals.

Gastroesophageal Reflux Disease Epidemiology Segmentation

DelveInsight’s Gastroesophageal Reflux Disease market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Gastroesophageal Reflux Disease historical patient pools and forecasted Gastroesophageal Reflux Disease patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Gastroesophageal Reflux Disease Market report proffers epidemiological analysis for the study period 2020-32 in the 7MM segmented into:

Gastroesophageal Reflux Disease Prevalence
Age-Specific Gastroesophageal Reflux Disease Prevalence
Gender-Specific Gastroesophageal Reflux Disease Prevalence
Diagnosed and Treatable Cases of Gastroesophageal Reflux Disease

Visit for more @ Gastroesophageal Reflux Disease Epidemiological Insights

Gastroesophageal Reflux Disease Market Insights:

Several major companies, including Alexion Pharmaceuticals, Novartis, and Roche, are leading the Gastroesophageal Reflux Disease (aHUS) treatment landscape. The market details, broken down by country and therapy, are outlined below.
According to DelveInsight’s patient-based forecasting model, the total aHUS market size in the 7MM was approximately USD 1,300 million in 2023, and significant growth is anticipated during the forecast period due to the introduction of new therapies.
In 2023, the United States accounted for the largest share of the aHUS market in the 7MM, approximately 70%, followed by Germany and France.
Among emerging therapies for aHUS, Novartis’ iptacopan and Roche’s crovalimab are expected to play a pivotal role in transforming the market. By 2034, iptacopan is projected to generate the highest revenue among emerging treatments, with nearly USD 100 million expected in the EU4 and the UK.

Gastroesophageal Reflux Disease Market Outlook

The management of GERD is divided into five stages: four stages of medical management and one stage involving surgical intervention. The goal of treatment is to reduce esophageal exposure to reflux, alleviate symptoms, heal the esophagus, prevent complications, and maintain remission. Most GERD patients can manage symptoms and promote healing through lifestyle changes and drug therapy without requiring surgery. Surgery is considered for those with severe symptoms, erosive esophagitis, or disease complications despite adequate medication.

Lifestyle changes, such as elevating the head of the bed, reducing fat intake, quitting smoking, limiting alcohol, losing weight, and avoiding large meals and certain foods, are essential throughout treatment.

For mild symptoms, periodic drug therapy is often necessary, using antacids, alginic acid, or over-the-counter H2-receptor blockers. Antacids offer quick symptom relief by neutralizing gastric acid but are not used alone for esophageal healing due to their high dosage requirements. Alginic acid forms a mechanical barrier over the refluxate, protecting the esophagus. H2-receptor blockers provide longer relief, making them more suitable for symptom prevention.

For moderate to severe symptoms, scheduled pharmacologic therapy is required. Proton pump inhibitors (PPIs), such as Dexilant (dexlansoprazole), are used to suppress gastric acid, heal esophagitis, and maintain remission.

Surgery may be needed if medical therapy fails or complications arise, such as large hiatal hernia, Barrett’s esophagus, severe esophagitis, recurrent strictures, or significant pulmonary symptoms. Noncompliance, financial barriers, and relapse of symptoms can also contribute to the need for surgery.

Gastroesophageal Reflux Disease Marketed Drugs

VOQUEZNA (vonoprazan): Phathom Pharmaceuticals, Inc.

Gastroesophageal Reflux Disease Emerging Drugs

BLI5100 (Tegoprazan): Braintree/ Sebela Pharmaceuticals

Gastroesophageal Reflux Disease Key Companies

ddpharma, Arog Pharmaceuticals, Chong Kun Dang Pharmaceutical, Cinclus Pharma, Cogent Biosciences, Daewoong Pharmaceutical, HK inno.N Corporation, Jeil Pharmaceutical, Onconic Therapeutics, Plexxikon, Renexxion, Taiho Pharmaceutical, Takeda, Trio Medicines, and others

For more information, visit Gastroesophageal Reflux Disease Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Gastroesophageal Reflux Disease Market Report:

11 Years Forecast
7MM Coverage
Descriptive overview of Gastroesophageal Reflux Disease, causes, signs and symptoms, diagnosis, treatment
Comprehensive insight into Gastroesophageal Reflux Disease epidemiology in the 7MM
Gastroesophageal Reflux Disease marketed and emerging therapies
Gastroesophageal Reflux Disease companies
Gastroesophageal Reflux Disease market drivers and barriers

Table of Contents:

1 Gastroesophageal Reflux Disease Market Key Comprehensive Insights

2 Gastroesophageal Reflux Disease Market Report Introduction

3 Competitive Intelligence Analysis for Gastroesophageal Reflux Disease

4 Gastroesophageal Reflux Disease Market Analysis Overview at a Glance

5 Executive Summary of Gastroesophageal Reflux Disease

6 Gastroesophageal Reflux Disease Epidemiology and Market Methodology

7 Gastroesophageal Reflux Disease Epidemiology and Patient Population

8 Gastroesophageal Reflux Disease Patient Journey

9 Gastroesophageal Reflux Disease Treatment Algorithm, Gastroesophageal Reflux Disease Current Treatment, and Medical Practices

10 Key Endpoints in Gastroesophageal Reflux Disease Clinical Trials

11 Gastroesophageal Reflux Disease Marketed Therapies

12 Gastroesophageal Reflux Disease Emerging Therapies

13 Gastroesophageal Reflux Disease: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Gastroesophageal Reflux Disease

16 Gastroesophageal Reflux Disease Market Key Opinion Leaders Reviews

18 Gastroesophageal Reflux Disease Market Drivers

19 Gastroesophageal Reflux Disease Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Gastroesophageal Reflux Disease Epidemiology 2034

DelveInsight’s “Gastroesophageal Reflux Disease – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Gastroesophageal Reflux Disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Gastroesophageal Reflux Disease Pipeline 2024

“Gastroesophageal Reflux Disease Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Gastroesophageal Reflux Disease market. A detailed picture of the Gastroesophageal Reflux Disease pipeline landscape is provided, which includes the disease overview and Gastroesophageal Reflux Disease treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Gastroesophageal Reflux Disease Market Expected to rise, 2034 | ddpharma, Arog Pharmaceuticals, Chong Kun Dang Pharmaceutical, Cinclus Pharma, Cogent Biosciences, Daewoong Pharmaceutical, HK inno

Adam Golob’s Nemesis Rising Offers a Haunting Exploration of Survival and the Fragile Boundaries of Humanity

With stark prose, relentless tension, and psychological and emotional turmoil, Nemesis Rising by Adam Golob examines one man’s journey through love, death, hatred, and transformation into someone–or something–that endures.

Adam Golob, Ph.D., is a dynamic educator, researcher, and award-winning author specializing in political science, interdisciplinary studies, and regional studies.

As an Assistant Professor at Gulf Coast State College, Adam is celebrated for his engaging teaching style and commitment to fostering critical thinking and inclusivity. He serves as a faculty advisor to several social justice organizations, actively contributing to equity programs, and frequently presenting on pressing topics including governance, climate politics, and human rights.

Adam’s research focuses on human trafficking, exploitation, and the intersections of justice and resilience. His expertise has made him a sought-after country conditions expert for asylum and refugee cases, where he delivers his professional expertise.

As an author, Adam has published extensively on issues of social justice, governance, and human rights. His debut novel, Nemesis Rising, merges his scholarly insight with his creative instincts, exploring themes of survival and morality. The novel has already garnered critical acclaim, earning first-place honors at the International Impact Book Awards and The Book Fest Awards. This one-on-one interview shares Adam’s background and experience writing Nemesis Rising.

Tell us about Nemesis Rising.

The year is 2045 and the criminal justice system has undergone a massive overhaul. The death penalty has been overturned, but in exchange, top-tier criminals serve life sentences in the infamous Zynum Prison.

Sam Anderson is a dedicated middle school history teacher who has just been framed and convicted for the murder of his fiancée. His sentence: a lifetime in Zynum Prison.

Set within a decaying, domed city-prison where survival supersedes morality, the story chronicles Sam’s struggle to maintain his humanity amid chaos. As alliances form and tensions rise, he must navigate treacherous clans, violent raids, the potential for love amid the desolation, and the oppressive rule of the self-proclaimed “King of Zynum,” a tyrant who embodies the prison’s descent into savagery. The two central characters include Sam and Gabrielle, a young woman born in the prison. Together, they forge bonds to confront the harsh realities of their existence. The novel delves into themes of survival, morality, theology, and the resilience of the human spirit in a world that has abandoned redemption.

What inspired you to write Nemesis Rising?

The intersection of my passions for education, psychology, politics and interest in exploring human resilience, inspired me to write Nemesis Rising.

The philosophy of human nature has always been an interest of mine, and I wanted to create a protagonist who embodies the crux of it all. The story grew from my fascination with the moral dilemmas we face when survival challenges our humanity. I envisioned a world where justice is corrupted and characters are stripped to their rawest forms, forced to choose between who they are and what they must become.

Through Sam’s journey, I aimed to explore how hope, connection, and identity persist (or don’t) in the bleakest circumstances. Ultimately, I wanted to inspire readers to question how far they would go to protect their humanity while surviving unimaginable odds.

How did your background and experience influence your writing?

My background in academia deeply influenced my journey into literary fiction. My experiences teaching on governance and researching social justice have shaped my understanding of human dynamics and the way people can and do treat one another when left to their own devices.

In Nemesis Rising, I sought to merge my intellectual background with my creative instincts, creating a narrative that is both thrilling and reflective of universal struggles. By immersing themselves in this harrowing tale, I hope readers gain a deeper understanding of the fragility and strength of the human spirit, and perhaps, see their own lives mirrored or distortedly reflected in Sam’s narrative. They should appreciate the choices and connections that shape who they are. It is a narrative I want readers to not forget.

What is one message you would like readers to remember?

We are all the heroes of our own stories. However, when push comes to shove, survival often demands choices that challenge the essence of our humanity. Hope, connection, and purpose are the core of humanity, no matter the circumstances.

Through Sam’s journey, I want readers to reflect on their own boundaries—how far they would go to endure, and what they would hold onto when everything else is stripped away. The story explores resilience, morality, and transformation, prompting readers to question what it truly means to be human.

Purchasing the Book

Nemesis Rising has received positive reviews from well-known literary organizations, authors, and reviewers around the world. Reader Views writes, “Told with passion and skill, Adam Golob’s novel is…authentic and entertaining…making it very hard to put it down.” An Online Book Club reviewer writes, “It is my utmost pleasure to rate it 5 out of 5 stars. I will recommend it to those who love reading books on survival.”

The book is available for sale on Amazon and other online bookstores. Readers are encouraged to purchase their copy today: https://www.amazon.com/Nemesis-Rising-Adam-Golob/dp/B0CNYFQ2R9

To connect with Adam and learn more about his work, visit: https://tgolob8.wixsite.com/author. You can also find him on Facebook, Instagram and LinkedIn.

Media Contact
Company Name: Author News Network
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: authornewsnetwork.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Adam Golob’s Nemesis Rising Offers a Haunting Exploration of Survival and the Fragile Boundaries of Humanity

Cutaneous Lupus Erythematosus Market Set to Grow Substantially Through 2034, DelveInsight Projects | Biogen, Horizon Therapeutics, Bristol–Myers Squibb, AstraZeneca, Sanofi, Amgen, Gilead Sciences

The Key Cutaneous Lupus Erythematosus Companies in the market include – Biogen, Horizon Therapeutics, Bristol–Myers Squibb, AstraZeneca, Sanofi, Amgen, Gilead Sciences, Pfizer, Bristol-Myers Squibb, Novartis, Rigel Pharmaceuticals, Merck, and others.

DelveInsight’s “Cutaneous Lupus Erythematosus Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Cutaneous Lupus Erythematosus, historical and forecasted epidemiology as well as the Cutaneous Lupus Erythematosus market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Cutaneous Lupus Erythematosus, offering comprehensive insights into the Cutaneous Lupus Erythematosus revenue trends, prevalence, and treatment landscape. The report delves into key Cutaneous Lupus Erythematosus statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Cutaneous Lupus Erythematosus therapies. Additionally, we cover the landscape of Cutaneous Lupus Erythematosus clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Cutaneous Lupus Erythematosus treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Cutaneous Lupus Erythematosus space.

To Know in detail about the Cutaneous Lupus Erythematosus market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Cutaneous Lupus Erythematosus Market Forecast

Some of the key facts of the Cutaneous Lupus Erythematosus Market Report:

The Cutaneous Lupus Erythematosus market size was valued ~USD 500 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
In October 2024, ImmuneSensor Therapeutics, a clinical-stage biotherapeutics company specializing in the development of innovative inhibitors and agonists targeting the cGAS-STING pathway for peripheral and CNS conditions in inflammation, autoimmunity, and oncology, announced today the completion of dosing for the first cohort of healthy volunteers in a Phase 1 randomized, double-blind, placebo-controlled trial. This study evaluates its lead oral cGAS inhibitor, IMSB301, which is under development for treating various inflammatory and autoimmune diseases.
The United States holds the largest market size for Cutaneous Lupus Erythematosus, estimated at approximately USD 400 million, surpassing the markets of EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
In 2023, the total diagnosed prevalent cases of Cutaneous Lupus Erythematosus across the 7MM were approximately 800,000 and are expected to rise throughout the forecast period.

Key Cutaneous Lupus Erythematosus Companies: Biogen, Horizon Therapeutics, Bristol–Myers Squibb, AstraZeneca, Sanofi, Amgen, Gilead Sciences, Pfizer, Bristol-Myers Squibb, Novartis, Rigel Pharmaceuticals, Merck, and others
Key Cutaneous Lupus Erythematosus Therapies: Litifilimab, Daxdilimab, SOTYKTU, Anifrolumab, SAR443122, CC-11050, Litifilimab, Lanraplenib, PF-06823859, Deucravacitinib, KRP20, R932333, M5049, and others
The Cutaneous Lupus Erythematosus market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Cutaneous Lupus Erythematosus pipeline products will significantly revolutionize the Cutaneous Lupus Erythematosus market dynamics.
Chronic Cutaneous Lupus Erythematosus has been found to be more prevalent among the diagnosed population compared to other types in the 7MM. In the United States alone, it accounted for approximately 340,000 cases in 2023.
Within the EU4 and the UK, the United Kingdom reported the highest number of diagnosed prevalent cases, followed by France, while Spain had the lowest, with approximately 40,000 cases.
In 2023, the US represented approximately 60% of all diagnosed prevalent cases of Cutaneous Lupus Erythematosus (CLE) across the 7MM.
Within the EU4 and the UK, the UK reported the highest diagnosed prevalence of Cutaneous Lupus Erythematosus (CLE) in 2023, with approximately 80,000 cases, whereas Spain had the lowest, with around 40,000 cases.
Japan recorded approximately 66,000 diagnosed prevalent cases of Cutaneous Lupus Erythematosus (CLE) in 2023.
In 2023, the United States had approximately 478,000 diagnosed prevalent cases of Cutaneous Lupus Erythematosus (CLE).

Cutaneous Lupus Erythematosus Overview

Cutaneous Lupus Erythematosus (CLE) is a form of lupus that primarily affects the skin, causing inflammation and various skin lesions. It can occur independently or as part of systemic lupus erythematosus (SLE). CLE is classified into subtypes, including acute, subacute, and chronic forms, with symptoms like rashes, redness, and scaly patches, often triggered by sunlight exposure. The condition can vary in severity and may leave scars or pigmentation changes. Diagnosis involves clinical evaluation, skin biopsy, and laboratory tests. Treatment typically includes sun protection, topical steroids, immunosuppressants, and antimalarial medications to manage symptoms and prevent flare-ups.

Get a Free sample for the Cutaneous Lupus Erythematosus Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/cutaneous-lupus-erythematosus-market

Cutaneous Lupus Erythematosus Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Cutaneous Lupus Erythematosus Epidemiology Segmentation:

The Cutaneous Lupus Erythematosus market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Diagnosed Prevalent Cases of CLE in the 7MM
Prevalent cases of CLE by Gender in the 7MM
Prevalent Cases of CLE by Type in the 7MM
Prevalent Cases of CLE by Severity in the 7MM
Total Treated Cases of CLE in the 7MM

Download the report to understand which factors are driving Cutaneous Lupus Erythematosus epidemiology trends @ Cutaneous Lupus Erythematosus Epidemiology Forecast

Cutaneous Lupus Erythematosus Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cutaneous Lupus Erythematosus market or expected to get launched during the study period. The analysis covers Cutaneous Lupus Erythematosus market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Cutaneous Lupus Erythematosus Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Cutaneous Lupus Erythematosus Therapies and Key Companies

Litifilimab: Biogen
Daxdilimab: Horizon Therapeutics
SOTYKTU: Bristol–Myers Squibb
Anifrolumab: AstraZeneca
SAR443122: Sanofi
CC-11050: Amgen
Litifilimab: Biogen
Lanraplenib: Gilead Sciences
PF-06823859: Pfizer
Deucravacitinib: Bristol-Myers Squibb
KRP203: Novartis
R932333: Rigel Pharmaceuticals
M5049: Merck

Discover more about therapies set to grab major Cutaneous Lupus Erythematosus market share @ Cutaneous Lupus Erythematosus Treatment Landscape

Cutaneous Lupus Erythematosus Market Strengths

A growing body of research focused on understanding the pathogenesis of CLE, which could lead to the development of more targeted and effective treatment.
The definition of cutaneous lupus is being refined to facilitate diagnostic and research protocols along with improved guidelines. Further, unique features of disease subtypes are being defined.

Cutaneous Lupus Erythematosus Market Opportunities

Research into the pathogenesis of CLE is accelerating, and discoveries are identifying genetic and epigenetic changes. Continued research on mechanisms driving CLE will provide new methods for preventing and treating cutaneous lesions.
The lack of a cure for CLE provides a massive opportunity to launch effective novel therapies and targeted treatments in the emerging pipeline to take over the current market.

Scope of the Cutaneous Lupus Erythematosus Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Cutaneous Lupus Erythematosus Companies: Biogen, Horizon Therapeutics, Bristol–Myers Squibb, AstraZeneca, Sanofi, Amgen, Gilead Sciences, Pfizer, Bristol-Myers Squibb, Novartis, Rigel Pharmaceuticals, Merck, and others
Key Cutaneous Lupus Erythematosus Therapies: Litifilimab, Daxdilimab, SOTYKTU, Anifrolumab, SAR443122, CC-11050, Litifilimab, Lanraplenib, PF-06823859, Deucravacitinib, KRP20, R932333, M5049, and others
Cutaneous Lupus Erythematosus Therapeutic Assessment: Cutaneous Lupus Erythematosus current marketed and Cutaneous Lupus Erythematosus emerging therapies
Cutaneous Lupus Erythematosus Market Dynamics: Cutaneous Lupus Erythematosus market drivers and Cutaneous Lupus Erythematosus market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Cutaneous Lupus Erythematosus Unmet Needs, KOL’s views, Analyst’s views, Cutaneous Lupus Erythematosus Market Access and Reimbursement

To know more about Cutaneous Lupus Erythematosus companies working in the treatment market, visit @ Cutaneous Lupus Erythematosus Clinical Trials and Therapeutic Assessment

Table of Contents

1. Cutaneous Lupus Erythematosus Market Report Introduction

2. Executive Summary for Cutaneous Lupus Erythematosus

3. SWOT analysis of Cutaneous Lupus Erythematosus

4. Cutaneous Lupus Erythematosus Patient Share (%) Overview at a Glance

5. Cutaneous Lupus Erythematosus Market Overview at a Glance

6. Cutaneous Lupus Erythematosus Disease Background and Overview

7. Cutaneous Lupus Erythematosus Epidemiology and Patient Population

8. Country-Specific Patient Population of Cutaneous Lupus Erythematosus

9. Cutaneous Lupus Erythematosus Current Treatment and Medical Practices

10. Cutaneous Lupus Erythematosus Unmet Needs

11. Cutaneous Lupus Erythematosus Emerging Therapies

12. Cutaneous Lupus Erythematosus Market Outlook

13. Country-Wise Cutaneous Lupus Erythematosus Market Analysis (2020–2034)

14. Cutaneous Lupus Erythematosus Market Access and Reimbursement of Therapies

15. Cutaneous Lupus Erythematosus Market Drivers

16. Cutaneous Lupus Erythematosus Market Barriers

17. Cutaneous Lupus Erythematosus Appendix

18. Cutaneous Lupus Erythematosus Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cutaneous Lupus Erythematosus Market Set to Grow Substantially Through 2034, DelveInsight Projects | Biogen, Horizon Therapeutics, Bristol–Myers Squibb, AstraZeneca, Sanofi, Amgen, Gilead Sciences

Fragile X Syndrome Market Expected to rise, 2034 | Confluence Pharmaceuticals, Ovid Therapeutics, Neuren Pharmaceuticals, Zynerba Pharmaceuticals, Tetra Therapeutics, Autifony Therapeutics, Prilenia

“Fragile X Syndrome market”

The Fragile X Syndrome market growth is driven by factors like increase in the prevalence of Fragile X Syndrome, investments in research and development, entry of emerging therapies during the study period 2020-2034.

The Fragile X Syndrome market report also offers comprehensive insights into the Fragile X Syndrome market size, share, Fragile X Syndrome epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Fragile X Syndrome market size growth forward.

Some of the key highlights from the Fragile X Syndrome Market Insights Report:

Several key pharmaceutical companies, including Confluence Pharmaceuticals, Ovid Therapeutics, Neuren Pharmaceuticals, Zynerba Pharmaceuticals, Tetra Therapeutics, Autifony Therapeutics, Prilenia Therapeutics, Alcobra Ltd., Seaside Therapeutics, Inc., Marinus Pharmaceuticals, Novartis, Neuren Pharmaceuticals, Hoffmann-La Roche, Healx, Nova Mentis, Lysogene, Actinogen, Prilenia Therapeutics, Confluence Pharmaceuticals, Sentinel Oncology, and others, are developing novel products to improve the Fragile X Syndrome treatment outlook.
In March 2022, the European Commission granted orphan drug designation to Zygel, a cannabidiol (CBD) transdermal gel developed by Zynerba Pharmaceuticals, to treat behavioral symptoms associated with Fragile X syndrome.
In February 2022, Ovid entered into an agreement with Healx, granting them an exclusive option to license gaboxadol (OV101). Healx plans to explore this compound as a potential part of a combination therapy for Fragile X syndrome and other conditions.
In December 2021, Nova Mentis Life Science and Mycrodose Therapeutics announced the successful integration of NOVA’s psilocybin-based drug development program with Mycrodose’s transdermal technology to address Fragile X syndrome.
In September 2021, The McQuade Center for Strategic Research and Development, part of Otsuka’s global pharmaceutical network, entered into a collaboration with Sentinel Oncology to support clinical development of a first-in-class treatment for Fragile X syndrome.
In October 2021, Nova Mentis’ psilocybin drug received orphan drug designation from the European Medicines Agency for its potential use in treating Fragile X syndrome.
According to DelveInsight’s estimates, in 2023, approximately 122,000 prevalent cases of Fragile X syndrome were diagnosed across the 7MM. The United States accounted for 58% of these cases, while the EU4 and the UK represented 31%, and Japan accounted for 11%.
The market for Fragile X syndrome therapies is expected to experience steady growth, with an estimated compound annual growth rate (CAGR) of about 7% from 2024 to 2034. This growth is driven by the introduction of new treatments like Zygel and BPN14770, along with advancements in diagnostic technologies and ongoing research focused on genetic mechanisms of the disorder.
Despite progress in understanding Fragile X syndrome, there remains a notable gap in effective, approved treatments targeting the core symptoms. Timely and accurate diagnosis is still a challenge, limiting early intervention.
The market faces several obstacles, including high clinical trial failure rates due to the varied behavioral phenotypes among patients. Additionally, the lack of approved treatments, regulatory hurdles, and the need for extensive research hinder market growth.
The competitive landscape for Fragile X syndrome treatments is intensifying, with several companies vying for market share by leveraging orphan drug designations. Ongoing clinical trials and strategic partnerships are focused on bringing new treatment options to the forefront. Notable therapies under development include Zygel and BPN14770.
In July 2024, Zatolmilast received fast-track designation from the US FDA for the treatment of Fragile X syndrome, expediting its development and review process to increase patient access.
As per DelveInsight analysis, the Fragile X Syndrome market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Fragile X Syndrome Market Landscape

Fragile X Syndrome Overview

Fragile X Syndrome is a genetic condition caused by a mutation in the FMR1 gene on the X chromosome, which leads to intellectual disabilities, developmental delays, and behavioral issues. This mutation causes a deficiency in the fragile X mental retardation protein (FMRP), which is crucial for proper brain development. The syndrome is marked by intellectual disabilities, typically mild to moderate in males and mild in females. Physical traits may include a long, narrow face, large ears, flexible fingers, and enlarged testicles in males. Behavioral symptoms often resemble those of autism spectrum disorder, along with hyperactivity and seizures.

The diagnosis of Fragile X syndrome is confirmed through genetic testing to measure the number of CGG repeats in the FMR1 gene. Normally, there are 5 to 40 repeats, but Fragile X syndrome occurs with more than 200 repeats. Molecular genetic tests are used to assess both the number of CGG repeats and the methylation status of the FMR1 gene. Prenatal testing methods, such as chorionic villus sampling and amniocentesis, can also be used to detect the syndrome in fetuses.

Do you know the treatment paradigms for different countries? Download our Fragile X Syndrome Market Sample Report

Fragile X Syndrome Epidemiology Insights

In 2023, the United States saw about 42 thousand males and 29 thousand females diagnosed with Fragile X syndrome, showing a higher prevalence among males than females. In Japan, the distribution of cases in 2023 included approximately 5,700 cases in the 0–11 age group, 2,300 cases in the 12–17 age group, and 5,000 cases in those over 18, reflecting different age-related prevalence rates.

Fragile X Syndrome Epidemiology Segmentation

DelveInsight’s Fragile X Syndrome market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Fragile X Syndrome historical patient pools and forecasted Fragile X Syndrome patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Fragile X Syndrome Market report proffers epidemiological analysis for the study period 2020-32 in the 7MM segmented into:

Fragile X Syndrome Prevalence
Age-Specific Fragile X Syndrome Prevalence
Gender-Specific Fragile X Syndrome Prevalence
Diagnosed and Treatable Cases of Fragile X Syndrome

Visit for more @ Fragile X Syndrome Epidemiological Insights

Fragile X Syndrome Market Outlook

Treatment for Fragile X syndrome primarily focuses on managing its associated symptoms through pharmacological interventions. These may include stimulants for attention deficit and hyperactivity, selective serotonin reuptake inhibitors (SSRIs) for anxiety, antipsychotic medications for aggression and mood instability, and melatonin for sleep issues.

In boys with Fragile X syndrome, stimulants are commonly used to address hyperactivity, impulsivity, and distractibility, though their effectiveness and side effects can vary from person to person. In children under 5 years of age, stimulants may cause irritability and other behavioral issues, in which case non-stimulant medications may be considered.

SSRIs are often prescribed to manage mood disorders, anxiety, and obsessive-compulsive behaviors. These medications are particularly effective for reducing social anxiety, tantrums, and aggression. Fluoxetine can be particularly helpful for treating selective mutism.

If SSRIs are not tolerated due to side effects, other antidepressants such as Trazodone, Bupropion, and tricyclic antidepressants may be used. Clonidine and guanfacine are also sometimes prescribed for anxiety-like symptoms, especially those related to sensory sensitivities, although their effectiveness for other anxiety symptoms may be limited. Buspirone can reduce anxiety, either alone or alongside an SSRI.

Benzodiazepines are generally reserved for acute emotional crises with high anxiety but are not recommended for long-term use due to potential memory issues, increased confusion, and the risk of paradoxical effects like heightened hyperactivity and disinhibition.

Fragile X Syndrome Emerging Drugs

Zygel (ZYN002 Cannabidiol Gel): Harmony Biosciences
BPN14770: Tetra Therapeutics

Fragile X Syndrome Key Companies

Confluence Pharmaceuticals, Ovid Therapeutics, Neuren Pharmaceuticals, Zynerba Pharmaceuticals, Tetra Therapeutics, Autifony Therapeutics, Prilenia Therapeutics, Alcobra Ltd., Seaside Therapeutics, Inc., Marinus Pharmaceuticals, Novartis, Neuren Pharmaceuticals, Hoffmann-La Roche, Healx, Nova Mentis, Lysogene, Actinogen, Prilenia Therapeutics, Confluence Pharmaceuticals, Sentinel Oncology, and others

For more information, visit Fragile X Syndrome Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Fragile X Syndrome Market Report:

11 Years Forecast
7MM Coverage
Descriptive overview of Fragile X Syndrome, causes, signs and symptoms, diagnosis, treatment
Comprehensive insight into Fragile X Syndrome epidemiology in the 7MM
Fragile X Syndrome marketed and emerging therapies
Fragile X Syndrome companies
Fragile X Syndrome market drivers and barriers

Table of Contents:

1 Fragile X Syndrome Market Key Comprehensive Insights

2 Fragile X Syndrome Market Report Introduction

3 Competitive Intelligence Analysis for Fragile X Syndrome

4 Fragile X Syndrome Market Analysis Overview at a Glance

5 Executive Summary of Fragile X Syndrome

6 Fragile X Syndrome Epidemiology and Market Methodology

7 Fragile X Syndrome Epidemiology and Patient Population

8 Fragile X Syndrome Patient Journey

9 Fragile X Syndrome Treatment Algorithm, Fragile X Syndrome Current Treatment, and Medical Practices

10 Key Endpoints in Fragile X Syndrome Clinical Trials

11 Fragile X Syndrome Marketed Therapies

12 Fragile X Syndrome Emerging Therapies

13 Fragile X Syndrome: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Fragile X Syndrome

16 Fragile X Syndrome Market Key Opinion Leaders Reviews

18 Fragile X Syndrome Market Drivers

19 Fragile X Syndrome Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Fragile X Syndrome Epidemiology 2034

DelveInsight’s “Fragile X Syndrome – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Fragile X Syndrome epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Fragile X Syndrome Pipeline 2024

“Fragile X Syndrome Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Fragile X Syndrome market. A detailed picture of the Fragile X Syndrome pipeline landscape is provided, which includes the disease overview and Fragile X Syndrome treatment guidelines.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Fragile X Syndrome Market Expected to rise, 2034 | Confluence Pharmaceuticals, Ovid Therapeutics, Neuren Pharmaceuticals, Zynerba Pharmaceuticals, Tetra Therapeutics, Autifony Therapeutics, Prilenia

Non-Alcoholic Steatohepatitis Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Madrigal Pharmac, Inventiva Pharma, Zydus Therapeutics, Novo Nordisk A/S, Viking

The Key Non-Alcoholic Steatohepatitis Companies in the market include – Madrigal Pharmaceuticals, Inventiva Pharma, Zydus Therapeutics, Novo Nordisk A/S, Viking Therapeutics, Hepagene, Enyo Pharma, Galectin Therapeutics Inc., 89bio, Inc., Akero Therapeutics, Inc, NeuroBo Pharmaceuticals Inc, Novo Nordisk A/S, J2H Biotech, Haisco Pharmaceutical, Altimmune, Inc., AstraZeneca, Boehringer Ingelheim, Can-Fite BioPharma, Madrigal Pharmaceuticals, GlaxoSmithKline, and others.

DelveInsight’s “Non-Alcoholic Steatohepatitis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Non-Alcoholic Steatohepatitis, historical and forecasted epidemiology as well as the Non-Alcoholic Steatohepatitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Non-Alcoholic Steatohepatitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Non-Alcoholic Steatohepatitis Market Forecast

Some of the key facts of the Non-Alcoholic Steatohepatitis Market Report:

The total NASH market size in the 7MM was estimated at around ~USD 2,114 million in 2023 and is expected to grow significantly throughout the forecast period (2024–2034).
In November 2024, Novo Nordisk reported favorable outcomes for semaglutide in the treatment of Nonalcoholic Steatohepatitis (NASH). The Phase 3 Essence trial demonstrated that a once-weekly 2.4 mg dose of semaglutide effectively improved liver fibrosis and resolved steatohepatitis in NASH patients with stage 2 or 3 fibrosis, without aggravating liver fibrosis, successfully achieving the primary endpoints.
In October 2024, Sagimet Biosciences (SGMT) announced the successful completion of end-of-Phase 2 discussions with the FDA, clearing the path for denifanstat to progress into Phase 3 clinical trials for metabolic dysfunction-associated steatohepatitis.
In July 2024, Inventiva has provided updates on its Phase III NATiV3 clinical program evaluating lanifibranor for the treatment of metabolic dysfunction-associated steatohepatitis/non-alcoholic steatohepatitis (MASH/NASH). The recruitment process for the trial is currently ongoing at 347 sites in 19 countries.
In 2023, the United States led the Nonalcoholic Steatohepatitis (NASH) market within the 7MM, with an estimated market size of approximately USD 1,519 million, a figure anticipated to grow further by 2034.
In 2023, Germany recorded the highest NASH market size among European nations at USD 89 million, while Spain ranked the lowest at USD 50 million.
In 2023, Japan’s Nonalcoholic Steatohepatitis (NASH) market size was approximately USD 260 million and is projected to grow further by 2034.
In 2023, the United States reported the highest number of diagnosed prevalent cases of NASH, estimated at approximately 9.4 million. In comparison, the EU4 and the UK accounted for around 3.6 million cases, while Japan reported approximately 2.5 million cases.
Gender-based analysis revealed that the diagnosed prevalent cases of NASH were higher in males compared to females across the 7MM. Males accounted for approximately 56% of the total cases in the region.
In 2023, Japan represented around 16% of the total diagnosed prevalent cases of NASH within the 7MM. This number is anticipated to grow throughout the study period from 2020 to 2034.
Key Non-Alcoholic Steatohepatitis Companies: Madrigal Pharmaceuticals, Inventiva Pharma, Zydus Therapeutics, Novo Nordisk A/S, Viking Therapeutics, Hepagene, Enyo Pharma, Galectin Therapeutics Inc., 89bio, Inc., Akero Therapeutics, Inc, NeuroBo Pharmaceuticals Inc, Novo Nordisk A/S, J2H Biotech, Haisco Pharmaceutical, Altimmune, Inc., AstraZeneca, Boehringer Ingelheim, Can-Fite BioPharma, Madrigal Pharmaceuticals, GlaxoSmithKline, 89bio, Inc., Akero Therapeutics, Inc, Regeneron Pharmaceuticals, Hepagene (Shanghai) Co., Ltd., Inventiva Pharma, Hanmi Pharmaceutical, Madrigal Pharmaceuticals, Inc., Sinew Pharma Inc., Boston Pharmaceuticals, and others
Key Non-Alcoholic Steatohepatitis Therapies: REZDIFFRA (resmetirom), Lanifibranor, Saroglitazar Magnesium, Semaglutide, VK2809, MGL-3196, HPG1860, Vonafexor (EYP001), Belapectin, Pegozafermin, Efruxifermin (EFX), DA-1241, NNC0194, J2H-1702, HSK31679, Pemvidutide, AZD9550, Survodutide, Namodenoson, Resmetirom, GSK4532990, BIO89-100, EFX, ALN-HSD, HPG1860, IVA337, HM15211, MGL-3196, SNP-610, BOS-580, and others
The Non-Alcoholic Steatohepatitis epidemiology based on gender analyzed that males have a slightly higher likelihood of being affected by NASH compared to females in the 7MM.
The Non-Alcoholic Steatohepatitis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Non-Alcoholic Steatohepatitis pipeline products will significantly revolutionize the Non-Alcoholic Steatohepatitis market dynamics.

Non-Alcoholic Steatohepatitis Overview

Non-Alcoholic Steatohepatitis (NASH) is a liver condition characterized by the accumulation of fat in the liver, inflammation, and liver cell damage, resembling alcoholic liver disease but occurring in individuals who consume little to no alcohol. NASH is considered a severe form of non-alcoholic fatty liver disease (NAFLD) and can lead to complications such as cirrhosis, liver failure, and hepatocellular carcinoma (liver cancer).

Get a Free sample for the Non-Alcoholic Steatohepatitis Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/nonalcoholic-steatohepatitis-nash-market

Non-Alcoholic Steatohepatitis Epidemiology

Non-Alcoholic Steatohepatitis Epidemiology Segmentation:

The Non-Alcoholic Steatohepatitis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Non-Alcoholic Steatohepatitis
Prevalent Cases of Non-Alcoholic Steatohepatitis by severity
Gender-specific Prevalence of Non-Alcoholic Steatohepatitis
Diagnosed Cases of Episodic and Chronic Non-Alcoholic Steatohepatitis

Download the report to understand which factors are driving Non-Alcoholic Steatohepatitis epidemiology trends @ Non-Alcoholic Steatohepatitis Epidemiology Forecast

Non-Alcoholic Steatohepatitis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Non-Alcoholic Steatohepatitis market or expected to get launched during the study period. The analysis covers Non-Alcoholic Steatohepatitis market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report also covers the Non-Alcoholic Steatohepatitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Non-Alcoholic Steatohepatitis Therapies and Key Companies

REZDIFFRA (resmetirom): Madrigal Pharmaceuticals
Lanifibranor: Inventiva Pharma
Saroglitazar Magnesium: Zydus Therapeutics
Semaglutide: Novo Nordisk A/S
VK2809: Viking Therapeutics
MGL-3196: Madrigal Pharmaceuticals, Inc
HPG1860: Hepagene
Vonafexor (EYP001): Enyo Pharma
Belapectin: Galectin Therapeutics Inc.
Pegozafermin: 89bio, Inc.
Efruxifermin (EFX): Akero Therapeutics, Inc
DA-1241: NeuroBo Pharmaceuticals Inc
NNC0194: Novo Nordisk A/S
J2H-1702: J2H Biotech
HSK31679: Haisco Pharmaceutical
Pemvidutide: Altimmune, Inc.
AZD9550: AstraZeneca
Survodutide: Boehringer Ingelheim
Namodenoson: Can-Fite BioPharma
Resmetirom: Madrigal Pharmaceuticals
GSK4532990: GlaxoSmithKline
BIO89-100: 89bio, Inc.
EFX: Akero Therapeutics, Inc
ALN-HSD: Regeneron Pharmaceuticals
HPG1860: Hepagene (Shanghai) Co., Ltd.
IVA337: Inventiva Pharma
HM15211: Hanmi Pharmaceutical
VK2809: Viking Therapeutics, Inc.
MGL-3196: Madrigal Pharmaceuticals, Inc.
SNP-610: Sinew Pharma Inc.
BOS-580: Boston Pharmaceuticals

Discover more about therapies set to grab major Non-Alcoholic Steatohepatitis market share @ Non-Alcoholic Steatohepatitis Treatment Landscape

Non-Alcoholic Steatohepatitis Market Strengths

Growing research activities and multiple clinical trials ongoing for NASH, suggests that the number of drugs is being developed that will strengthen the market.

Non-Alcoholic Steatohepatitis Market Opportunities

The large pool of patients suffering from NASH and lucrative opportunities for market growth create attractive prospects for key players to work in these areas

Scope of the Non-Alcoholic Steatohepatitis Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Non-Alcoholic Steatohepatitis Companies: Madrigal Pharmaceuticals, Inventiva Pharma, Zydus Therapeutics, Novo Nordisk A/S, Viking Therapeutics, Hepagene, Enyo Pharma, Galectin Therapeutics Inc., 89bio, Inc., Akero Therapeutics, Inc, NeuroBo Pharmaceuticals Inc, Novo Nordisk A/S, J2H Biotech, Haisco Pharmaceutical, Altimmune, Inc., AstraZeneca, Boehringer Ingelheim, Can-Fite BioPharma, Madrigal Pharmaceuticals, GlaxoSmithKline, 89bio, Inc., Akero Therapeutics, Inc, Regeneron Pharmaceuticals, Hepagene (Shanghai) Co., Ltd., Inventiva Pharma, Hanmi Pharmaceutical, Madrigal Pharmaceuticals, Inc., Sinew Pharma Inc., Boston Pharmaceuticals, and others
Key Non-Alcoholic Steatohepatitis Therapies: REZDIFFRA (resmetirom), Lanifibranor, Saroglitazar Magnesium, Semaglutide, VK2809, MGL-3196, HPG1860, Vonafexor (EYP001), Belapectin, Pegozafermin, Efruxifermin (EFX), DA-1241, NNC0194, J2H-1702, HSK31679, Pemvidutide, AZD9550, Survodutide, Namodenoson, Resmetirom, GSK4532990, BIO89-100, EFX, ALN-HSD, HPG1860, IVA337, HM15211, MGL-3196, SNP-610, BOS-580, and others
Non-Alcoholic Steatohepatitis Therapeutic Assessment: Non-Alcoholic Steatohepatitis current marketed and Non-Alcoholic Steatohepatitis emerging therapies
Non-Alcoholic Steatohepatitis Market Dynamics: Non-Alcoholic Steatohepatitis market drivers and Non-Alcoholic Steatohepatitis market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Non-Alcoholic Steatohepatitis Unmet Needs, KOL’s views, Analyst’s views, Non-Alcoholic Steatohepatitis Market Access and Reimbursement

To know more about Non-Alcoholic Steatohepatitis companies working in the treatment market, visit @ Non-Alcoholic Steatohepatitis Clinical Trials and Therapeutic Assessment

Table of Contents

1. Non-Alcoholic Steatohepatitis Market Report Introduction

2. Executive Summary for Non-Alcoholic Steatohepatitis

3. SWOT analysis of Non-Alcoholic Steatohepatitis

4. Non-Alcoholic Steatohepatitis Patient Share (%) Overview at a Glance

5. Non-Alcoholic Steatohepatitis Market Overview at a Glance

6. Non-Alcoholic Steatohepatitis Disease Background and Overview

7. Non-Alcoholic Steatohepatitis Epidemiology and Patient Population

8. Country-Specific Patient Population of Non-Alcoholic Steatohepatitis

9. Non-Alcoholic Steatohepatitis Current Treatment and Medical Practices

10. Non-Alcoholic Steatohepatitis Unmet Needs

11. Non-Alcoholic Steatohepatitis Emerging Therapies

12. Non-Alcoholic Steatohepatitis Market Outlook

13. Country-Wise Non-Alcoholic Steatohepatitis Market Analysis (2020–2034)

14. Non-Alcoholic Steatohepatitis Market Access and Reimbursement of Therapies

15. Non-Alcoholic Steatohepatitis Market Drivers

16. Non-Alcoholic Steatohepatitis Market Barriers

17. Non-Alcoholic Steatohepatitis Appendix

18. Non-Alcoholic Steatohepatitis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Non-Alcoholic Steatohepatitis Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Madrigal Pharmac, Inventiva Pharma, Zydus Therapeutics, Novo Nordisk A/S, Viking

Yvette Schmitter Named Managing Partner of Fusion Collective, Redefining Innovation, Inclusion, and Impact in Technology

Yvette’s Strategic Vision and Unique Leadership Style Set to Propel Fusion Collective’s Mission of Empowering the Tech Leaders of Tomorrow

New York, NY – Fusion Collective, the powerhouse consultancy at the forefront of redefining what it means to deliver bespoke, inclusive technology solutions, proudly announces the appointment of Yvette Schmitter as Managing Partner. This signals a bold new chapter for Fusion Collective, which continues to deliver Fortune 1000-caliber expertise to organizations of all sizes, blending cutting-edge innovation with a human-centered approach.

At Fusion Collective, Yvette will lead a team of developers, thought leaders, and technical advisors, combining their unparalleled expertise to design, build, and deploy ethical, humanized AI solutions that resonate beyond technology and into meaningful societal impact. Her ability to demystify complexity and inspire action aligns seamlessly with Fusion Collective’s mission of redefining what innovation can achieve when guided by inclusivity, resilience, and empathy.

Yvette Schmitter is not just a leader; she’s a movement. Known for strategically aligning organizational offerings with ever-evolving client needs, Yvette has built a legacy of delivering novel, bespoke solutions that drive tangible success. Her philosophy – connecting the right resources to the right problems for the right clients – has consistently set her apart as a transformative leader. Yvette, a disruptor with heart, has spent decades at the helm of complex digital transformations, championing inclusivity and scaling innovation to ensure technology works for everyone. Her dynamic leadership, rooted in empathy, ingenuity, and bold vision, will propel Fusion Collective’s mission to deliver tailored solutions that empower organizations to thrive in a world where agility, inclusivity, and equity are no longer optional—they’re essential.

Yvette’s journey is one of defiance, resilience, and transformation. From overcoming cultural and societal barriers as a young Black woman with an insatiable curiosity for technology to ascending as a trailblazer in her field, she embodies the power of rewriting the narrative. As a former Digital Architecture Partner at PwC and a globally recognized speaker, Yvette has pioneered advancements in AI, cloud computing, and blockchain. She has always relentlessly focused on uplifting people and creating equity and inclusion at scale.

“At Fusion Collective, we don’t believe in one-size-fits-all solutions, nor does Yvette Schmitter. Her approach to leadership mirrors our philosophy: thoughtful, tailored, and deeply impactful,” said Blake Crawford, Co-Founder of Fusion Collective. “With Yvette as Managing Partner, we’re not just charting a path to sustainable growth for our clients—we’re reshaping the fabric of what business innovation can achieve when inclusivity and technology work hand in hand.”

“The future of technology is about more than algorithms, data models, and systems—it’s about people,” said Schmitter. “True innovation uplifts, includes, and empowers everyone it touches. At Fusion Collective, I see an extraordinary opportunity to strategically align our expertise with the needs of our clients, driving and enabling success through bespoke solutions that uplift and empower. Together, we’re building a future, no world, where technology serves as a bridge, not a barrier, and creates a better, more inclusive world.”

Fusion Collective offers diverse services, including AI alignment, cybersecurity strategy, and advanced wireless solutions. The company has become a trusted ally for businesses navigating the complexities of modern technology landscapes by seamlessly blending technical expertise with an empathetic understanding of industry-specific challenges. Under Yvette’s leadership, Fusion Collective is poised to expand its impact, delivering outcomes and transformative experiences that redefine success.

Yvette’s vision for Fusion Collective is clear and bold: to harness its 150+ years of combined expertise to help organizations of all sizes evolve into resilient, inclusive tech leaders of tomorrow. Her leadership will ensure that Fusion Collective remains at the forefront of redefining success—transforming challenges into opportunities and delivering solutions that not only meet expectations but exceed them. With a proven track record of demystifying complex technologies and translating them into actionable strategies, Yvette will guide Fusion Collective in scaling its mission to be a partner of choice for forward-thinking businesses.

“With Yvette Schmitter at the helm, Fusion Collective is not just leading—it’s leaping. Leaping into a future where innovation isn’t just a tool for profit but a catalyst for change,” added Crawford. “Her vision, energy, and unmatched ability to connect people, ideas, and solutions coupled with her unwavering belief in the power of people are exactly what Fusion Collective—and the world—need right now.”

For more information about Fusion Collective, its services, and how Yvette Schmitter’s leadership is shaping the future of technology and inclusivity, please visit www.fusioncollective.net or contact blake@fusioncollective.net

About Yvette Schmitter

Yvette Schmitter is the Co-Founder and Managing Partner at Fusion Collective and a former Digital Architecture Partner at PwC. Yvette leads with a bold and inclusive vision: technology must serve everyone—regardless of gender, race, culture, or socioeconomic background. Her superpower lies in demystifying the complex, making technologies like AI and cloud computing not just understandable but transformative. For Yvette, innovation isn’t about shiny new tools; it’s about unlocking potential, leveling playing fields, and ensuring underrepresented voices have a seat at the table where decisions are made.

About Fusion Collective

At Fusion Collective, we redefine innovation by putting people at the center of technology. With over 150 years of combined expertise, we deliver tailored solutions that empower businesses to grow, thrive, and lead with impact. From cybersecurity and AI integration to global telecommunications and energy solutions, Fusion Collective bridges the gap between advanced technology and human potential, ensuring no challenge is too complex and no opportunity is out of reach.

Press Contact: Gabriela Bernadet, pr@yvetteschmitter.net

Yvette Schmitter LinkedIn: https://www.linkedin.com/in/yvetteschmitter/

Media Contact
Company Name: Yvette Schmitter
Contact Person: Gaby Bernadet
Email: Send Email
Country: United States
Website: www.fusioncollective.net

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Yvette Schmitter Named Managing Partner of Fusion Collective, Redefining Innovation, Inclusion, and Impact in Technology

Follicular Lymphoma Market Expected to rise, 2034 | Epizyme|Eisai, Bayer Healthcare Pharmaceuticals, Verastem Oncology, Gilead Sciences, TG Therapeutics, Bristol-Myers-Squibb, Roche, Incyte Corp

“Follicular Lymphoma Market”

The Follicular Lymphoma market growth is driven by factors like increase in the prevalence of Follicular Lymphoma, investments in research and development, entry of emerging therapies during the study period 2020-2034.

The Follicular Lymphoma market report also offers comprehensive insights into the Follicular Lymphoma market size, share, Follicular Lymphoma epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Follicular Lymphoma market size growth forward.

Some of the key highlights from the Follicular Lymphoma Market Insights Report:

Several key pharmaceutical companies, including Epizyme|Eisai, Bayer Healthcare Pharmaceuticals, Verastem Oncology, Gilead Sciences, TG Therapeutics, Bristol-Myers-Squibb, Roche, Incyte Corporation, Bristol Myers Squibb, ADC Therapeutics, MorphoSys, Nordic Nanovector, AbbVie, Regeneron Pharmaceuticals, Janssen Research & Development, Novartis, MEI Pharma, and BeiGene, and others, are developing novel products to improve the Follicular Lymphoma treatment outlook.
In August 2024, the company plans to submit a supplemental Biologics License Application for tafasitamab to treat FL patients who have failed at least one prior systemic anti-CD20 immunotherapy or chemo-immunotherapy, based on the positive Phase III results.
In June 2024, a consortium led by Eugene Private Equity and Korea Development Bank Private Equity announced they would acquire 80% of the South Korean vaccine maker Boryung Biopharma Co. for 320 billion won (USD 231 million).
In February 2024, Incyte revealed that it had entered into an asset purchase agreement with MorphoSys AG, granting Incyte exclusive global rights to tafasitamab. As a result, Incyte will take on revenue and costs for all U.S. commercialization and clinical development, while MorphoSys will no longer receive future milestone, profit split, or royalty payments.
As per DelveInsight analysis, the Follicular Lymphoma market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Follicular Lymphoma Market Landscape

Follicular Lymphoma Overview

Follicular lymphoma (FL) is a slow-growing B-cell lymphoproliferative disorder, mainly characterized by swollen lymph nodes, bone marrow involvement, and spleen enlargement, though extranodal involvement is rare. Common symptoms include fatigue, shortness of breath, night sweats, and weight loss, but many patients show no symptoms at the time of diagnosis. It is generally considered a chronic disease, as it is not typically curable, but patients often live many years with it.

The WHO grading system for FL classifies it into grades 1, 2, or 3 based on the number of centroblasts. Grade 1 (small cleaved cells) has 0–5 centroblasts/HPF, grade 2 (mixed) has 6–15 centroblasts/HPF, and grade 3 (large cell) has more than 15 centroblasts/HPF. Differentiating between grades 1/2 and grade 3 is clinically significant.

Diagnosis is made through histological examination of a lymph node or affected tissue biopsy. Immunohistochemical staining for CD19, CD20, CD10, monoclonal immunoglobulin, and bcl-2 protein is positive in nearly all cases, with a majority showing a t(14;18) translocation involving the IgH/bcl-2 genes.

Treatment depends on disease stage, with options including radiation, immunochemotherapy (Rituximab plus chemotherapy), and combinations like CHOP, CVP, or Bendamustine. Recent advances show that CAR T-cell therapy (like Yescarta) holds promise for treating indolent FL, with other CAR T options, Kymirah and Breyanzi, under investigation for relapsed/refractory cases. New bispecific antibodies, such as Mosunetuzumab and Odronextamab, are also showing promise, offering lower toxicity and easier administration.

Do you know the treatment paradigms for different countries? Download our Follicular Lymphoma Market Sample Report

Follicular Lymphoma Epidemiology Segmentation

DelveInsight’s Follicular Lymphoma market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Follicular Lymphoma historical patient pools and forecasted Follicular Lymphoma patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Follicular Lymphoma Market report proffers epidemiological analysis for the study period 2020-32 in the 7MM segmented into:

Follicular Lymphoma Prevalence
Age-Specific Follicular Lymphoma Prevalence
Gender-Specific Follicular Lymphoma Prevalence
Diagnosed and Treatable Cases of Follicular Lymphoma

Visit for more @ Follicular Lymphoma Epidemiological Insights

Follicular Lymphoma Market Outlook

Tazemetostat is the first oral EZH2 inhibitor approved for relapsed or refractory follicular lymphoma (FL) after two or more lines of treatment, or for EZH2 wild-type or unknown cases in patients with no satisfactory alternatives. EZH2, a histone methyltransferase prevalent in the germinal center where FL originates, is mutated in about 20% of FL cases. Tazemetostat inhibits both the mutated and wild-type forms of EZH2, with better response rates observed in patients with the mutated form.

In May 2019, the combination of lenalidomide (Revlimid) and rituximab (Rituxan, or R2) was approved for adult patients with previously treated grade 1–3A FL. This targeted therapy offers a new option, but with the upcoming patent expiry, generic lenalidomide is expected to enter the market soon.

Chimeric antigen receptor (CAR) T-cell therapy is another promising treatment. Gilead’s Kite recently received FDA accelerated approval for Yescarta, the first CAR-T cell therapy approved for indolent FL.

PI3K inhibitors, such as idelalisib, copanlisib, and duvelisib, are also significant treatments for relapsed or refractory FL, targeting the p110δ isoform of PI3K involved in B-cell development and signaling. Idelalisib, approved in 2014, is specifically indicated for relapsed FL but carries a boxed warning for severe side effects, including liver toxicity, diarrhea, colitis, pneumonitis, and intestinal perforation.

Follicular Lymphoma Emerging Drugs

Monjuvi/Tafasitamab (Incyte Corporation/MorphoSys)
Breyanzi/JCAR017 (Bristol Myers)

Follicular Lymphoma Key Companies

Epizyme|Eisai, Bayer Healthcare Pharmaceuticals, Verastem Oncology, Gilead Sciences, TG Therapeutics, Bristol-Myers-Squibb, Roche, Incyte Corporation, Bristol Myers Squibb, ADC Therapeutics, MorphoSys, Nordic Nanovector, AbbVie, Regeneron Pharmaceuticals, Janssen Research & Development, Novartis, MEI Pharma, and BeiGene, and others

For more information, visit Follicular Lymphoma Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Follicular Lymphoma Market Report:

11 Years Forecast
7MM Coverage
Descriptive overview of Follicular Lymphoma, causes, signs and symptoms, diagnosis, treatment
Comprehensive insight into Follicular Lymphoma epidemiology in the 7MM
Follicular Lymphoma marketed and emerging therapies
Follicular Lymphoma companies
Follicular Lymphoma market drivers and barriers

Table of Contents:

1 Follicular Lymphoma Market Key Comprehensive Insights

2 Follicular Lymphoma Market Report Introduction

3 Competitive Intelligence Analysis for Follicular Lymphoma

4 Follicular Lymphoma Market Analysis Overview at a Glance

5 Executive Summary of Follicular Lymphoma

6 Follicular Lymphoma Epidemiology and Market Methodology

7 Follicular Lymphoma Epidemiology and Patient Population

8 Follicular Lymphoma Patient Journey

9 Follicular Lymphoma Treatment Algorithm, Follicular Lymphoma Current Treatment, and Medical Practices

10 Key Endpoints in Follicular Lymphoma Clinical Trials

11 Follicular Lymphoma Marketed Therapies

12 Follicular Lymphoma Emerging Therapies

13 Follicular Lymphoma: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Follicular Lymphoma

16 Follicular Lymphoma Market Key Opinion Leaders Reviews

18 Follicular Lymphoma Market Drivers

19 Follicular Lymphoma Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Follicular Lymphoma Epidemiology 2034

DelveInsight’s “Follicular Lymphoma – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Follicular Lymphoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Follicular Lymphoma Pipeline 2024

“Follicular Lymphoma Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Follicular Lymphoma market. A detailed picture of the Follicular Lymphoma pipeline landscape is provided, which includes the disease overview and Follicular Lymphoma treatment guidelines.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Follicular Lymphoma Market Expected to rise, 2034 | Epizyme|Eisai, Bayer Healthcare Pharmaceuticals, Verastem Oncology, Gilead Sciences, TG Therapeutics, Bristol-Myers-Squibb, Roche, Incyte Corp

Metastatic Prostate Cancer Market to Expand Significantly by 2034, States DelveInsight Report | Merck, Arvinas Androgen Receptor, UNICANCER, Aragon Pharma, Mark Stein, Novartis, Orion Corporation

The Key Metastatic Prostate Cancer Companies: Curium US LLC, Bayer, Hookipa Biotech GmbH, University Health Network, Merck Sharp & Dohme, Arvinas Androgen Receptor, UNICANCER, Aragon Pharmaceuticals, Mark Stein, Novartis, Orion Corporation, Janssen Research & Development, AstraZeneca, MedSIR, Aragon Pharmaceuticals, Janssen Research & Development, Telix Pharmaceuticals, Alliance Foundation Trials, Epizyme, Inc., Exelixis, and others.

DelveInsight’s “Metastatic Prostate Cancer Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Metastatic Prostate Cancer, historical and forecasted epidemiology as well as the Metastatic Prostate Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Metastatic Prostate Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Metastatic Prostate Cancer Market Forecast

Some of the key facts of the Metastatic Prostate Cancer Market Report:

The Metastatic Prostate Cancer market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
In September 2024, Ipsen reported that the Phase III CONTACT-02 trial evaluating Cabometyx in combination with atezolizumab for mCRPC demonstrated a non-significant improvement in overall survival but successfully met the progression-free survival (PFS) endpoint.
In August 2024, Nuvation Bio announced that the US Food and Drug Administration has approved its investigational new drug application to study NUV-1511, the first clinical candidate developed from the company’s innovative drug-drug conjugate (DDC) platform.
In July 2024, The FDA has awarded fast-track designation to SYNC-T SV-102 for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
In June 2024, Kangpu Biopharmaceuticals secured FDA approval to conduct a Phase II/III trial of KPG-121 in combination with Abiraterone for metastatic castration-resistant prostate cancer (mCRPC).
In June 2024, BioNTech SE and Duality Biologics announced that the US Food and Drug Administration has granted Fast Track designation to BNT324/DB-1311 for the treatment of patients with advanced, unresectable, or metastatic castration-resistant prostate cancer (CRPC) who have progressed following standard systemic treatments.
In May 2024, Fusion Pharmaceuticals launched the Phase II AlphaBreak trial of FPI-2265 in patients with metastatic castration-resistant prostate cancer (mCRPC).
According to DelveInsight estimates, the total prevalent population of prostate cancer in the seven major markets (7MM) was approximately 8,241,400 cases in 2023. This number is expected to rise over the study period.
In 2023, the United States had the highest number of diagnosed prostate cancer cases, with approximately 1,506,200 reported cases.
In the US, the total diagnosed prevalent cases of prostate cancer by clinical stages were highest in locally advanced stages (Stage I–III), with over 903,700 cases in 2023, followed by biochemical recurrence/progressive and metastatic cases, respectively.
Key Metastatic Prostate Cancer Companies: Curium US LLC, Bayer, Hookipa Biotech GmbH, University Health Network, Merck Sharp & Dohme, Arvinas Androgen Receptor, UNICANCER, Aragon Pharmaceuticals, Mark Stein, Novartis, Orion Corporation, Janssen Research & Development, AstraZeneca, MedSIR, Aragon Pharmaceuticals, Janssen Research & Development, Telix Pharmaceuticals, Alliance Foundation Trials, Epizyme, Inc., Exelixis, and others
Key Metastatic Prostate Cancer Therapies: 177Lu-PSMA-I&T, Darolutamide (Nubeqa, BAY1841788), HB-302/HB-301, Enzalutamide, Opevesostat, Pembrolizumab, ARV-766 Part A&B, Darolutamide, Apalutamide, REGN2810, 177Lu-PSMA-617, ODM-208, Apalutamide, AZD0754, Enzalutamide, Apalutamide, Niraparib, 177Lu-DOTA-rosopatamb, Darolutamide, Tazemetostat, Cabozantinib, and others
The Metastatic Prostate Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Metastatic Prostate Cancer pipeline products will significantly revolutionize the Metastatic Prostate Cancer market dynamics.

Metastatic Prostate Cancer Overview

Metastatic prostate cancer is an advanced form of prostate cancer that has spread beyond the prostate gland to other parts of the body. This stage of prostate cancer, also known as stage IV, is characterized by the cancer’s ability to metastasize, meaning it travels through the bloodstream or lymphatic system to form new tumors in distant organs and tissues.

Get a Free sample for the Metastatic Prostate Cancer Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/metastatic-prostate-cancer-market

Metastatic Prostate Cancer Epidemiology

Metastatic Prostate Cancer Epidemiology Segmentation:

The Metastatic Prostate Cancer market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Metastatic Prostate Cancer
Prevalent Cases of Metastatic Prostate Cancer by severity
Gender-specific Prevalence of Metastatic Prostate Cancer
Diagnosed Cases of Episodic and Chronic Metastatic Prostate Cancer

Download the report to understand which factors are driving Metastatic Prostate Cancer epidemiology trends @ Metastatic Prostate Cancer Epidemiology Forecast

Metastatic Prostate Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Metastatic Prostate Cancer market or expected to get launched during the study period. The analysis covers Metastatic Prostate Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report also covers the Metastatic Prostate Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Metastatic Prostate Cancer Therapies and Key Companies

177Lu-PSMA-I&T: Curium US LLC
Darolutamide (Nubeqa, BAY1841788): Bayer
HB-302/HB-301: Hookipa Biotech GmbH
Enzalutamide: University Health Network
Opevesostat: Merck Sharp & Dohme
Pembrolizumab: Merck Sharp & Dohme
ARV-766 Part A&B: Arvinas Androgen Receptor
Darolutamide: UNICANCER
Apalutamide: Aragon Pharmaceuticals
REGN2810: Mark Stein
177Lu-PSMA-617: Novartis
ODM-208: Orion Corporation, Orion Pharma
Apalutamide: Janssen Research & Development
AZD0754: AstraZeneca
Enzalutamide: MedSIR
Apalutamide: Aragon Pharmaceuticals
Niraparib: Janssen Research & Development
177Lu-DOTA-rosopatamb: Telix Pharmaceuticals
Darolutamide: Alliance Foundation Trials
Tazemetostat: Epizyme, Inc.
Cabozantinib: Exelixis

Discover more about therapies set to grab major Metastatic Prostate Cancer market share @ Metastatic Prostate Cancer Treatment Landscape

Metastatic Prostate Cancer Market Strengths

The emergence of PASMA-PET imaging have significantly improved the diagnostic landscape of advance prostate cancer.
Astella’s XTANDI, which has approval in maximum prostate cancer indications is the highest revenue generator among all approved therapies in prostate cancer. Though XTANDI’s revenue is driven by prescribing volume, an increasing share of the drug’s revenue is driven by price increases in recent years.

Metastatic Prostate Cancer Market Opportunities

The developmental pipeline for mCSPC is dry compared to that of mCRPC. Thus, the market for mCSPC holds considerable scope for upcoming therapies owing to the availability of only a handful of approved drugs for its patient pool.
Although triplet therapy techniques have not yet been fully investigated, analysis shows that patients with de novo metastatic disease and a high-volume disease burden benefited most from this approach.

Scope of the Metastatic Prostate Cancer Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Metastatic Prostate Cancer Companies: Curium US LLC, Bayer, Hookipa Biotech GmbH, University Health Network, Merck Sharp & Dohme, Arvinas Androgen Receptor, UNICANCER, Aragon Pharmaceuticals, Mark Stein, Novartis, Orion Corporation, Janssen Research & Development, AstraZeneca, MedSIR, Aragon Pharmaceuticals, Janssen Research & Development, Telix Pharmaceuticals, Alliance Foundation Trials, Epizyme, Inc., Exelixis, and others
Key Metastatic Prostate Cancer Therapies: 177Lu-PSMA-I&T, Darolutamide (Nubeqa, BAY1841788), HB-302/HB-301, Enzalutamide, Opevesostat, Pembrolizumab, ARV-766 Part A&B, Darolutamide, Apalutamide, REGN2810, 177Lu-PSMA-617, ODM-208, Apalutamide, AZD0754, Enzalutamide, Apalutamide, Niraparib, 177Lu-DOTA-rosopatamb, Darolutamide, Tazemetostat, Cabozantinib, and others
Metastatic Prostate Cancer Therapeutic Assessment: Metastatic Prostate Cancer current marketed and Metastatic Prostate Cancer emerging therapies
Metastatic Prostate Cancer Market Dynamics: Metastatic Prostate Cancer market drivers and Metastatic Prostate Cancer market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Metastatic Prostate Cancer Unmet Needs, KOL’s views, Analyst’s views, Metastatic Prostate Cancer Market Access and Reimbursement

To know more about Metastatic Prostate Cancer companies working in the treatment market, visit @ Metastatic Prostate Cancer Clinical Trials and Therapeutic Assessment

Table of Contents

1. Metastatic Prostate Cancer Market Report Introduction

2. Executive Summary for Metastatic Prostate Cancer

3. SWOT analysis of Metastatic Prostate Cancer

4. Metastatic Prostate Cancer Patient Share (%) Overview at a Glance

5. Metastatic Prostate Cancer Market Overview at a Glance

6. Metastatic Prostate Cancer Disease Background and Overview

7. Metastatic Prostate Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of Metastatic Prostate Cancer

9. Metastatic Prostate Cancer Current Treatment and Medical Practices

10. Metastatic Prostate Cancer Unmet Needs

11. Metastatic Prostate Cancer Emerging Therapies

12. Metastatic Prostate Cancer Market Outlook

13. Country-Wise Metastatic Prostate Cancer Market Analysis (2020–2034)

14. Metastatic Prostate Cancer Market Access and Reimbursement of Therapies

15. Metastatic Prostate Cancer Market Drivers

16. Metastatic Prostate Cancer Market Barriers

17. Metastatic Prostate Cancer Appendix

18. Metastatic Prostate Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Metastatic Prostate Cancer Market to Expand Significantly by 2034, States DelveInsight Report | Merck, Arvinas Androgen Receptor, UNICANCER, Aragon Pharma, Mark Stein, Novartis, Orion Corporation

Diuretic and Anti-inflammatory Pill: A Patented Breakthrough for Managing Chronic Prostatitis Globally

“The herbs in Diuretic and Anti-inflammatory Pill work effectively and directly into reproductive system and urinary system, to completely clear up infections.”

Millions of men suffer from chronic prostatitis, a condition marked by persistent inflammation, pain, and other debilitating symptoms. Conventional treatments often fall short, driving the need for innovative solutions. The patented Diuretic and Anti-inflammatory Pill offers a new, research-backed approach to managing these symptoms effectively and safely. Learn how this groundbreaking therapy is transforming lives and redefining men’s health globally.

Chronic prostatitis is a widespread condition affecting millions of men worldwide, characterized by symptoms such as pelvic pain, urinary discomfort, feel tired and have general aches and pains. Despite its prevalence, effective treatment remains a challenge, particularly for non-bacterial prostatitis.

Traditional approaches, including antibiotics and anti-inflammatory drugs, often provide temporary relief but fail to address the root causes of inflammation. This has led to increased interest in comprehensive, multi-targeted therapies capable of offering long-term benefits.

The Need for Advanced Therapies

Non-bacterial prostatitis, a common subtype of chronic prostatitis, is particularly difficult to treat. While antibiotics are effective for bacterial cases, their misuse can lead to antibiotic resistance and disruption of the body’s natural microbiome. Other treatment options, such as alpha-blockers, are often limited to symptom management without addressing the underlying causes.

To bridge this gap, researchers and clinicians have explored holistic and integrative therapies, focusing on solutions that prioritize safety and efficacy.

A Patented Solution: Diuretic and Anti-inflammatory Pill

Diuretic and Anti-inflammatory Pill stands out as a patented herbal therapy specifically designed to address chronic prostatitis and related urogenital disorders. The formulation, backed by years of research and development, is publicly documented and can be verified through patent records. Its unique composition combines traditional wisdom with modern science, offering a natural yet scientifically validated approach to managing chronic prostatitis. You can check here: https://patents.google.com/patent/CN101637592B/en

Unique Advantages of the Diuretic and Anti-inflammatory Pill

1. Root Cause Treatment, Not Temporary Relief

Unlike traditional treatments that merely alleviate symptoms, this herbal remedy repairs damaged tissues, improves blood circulation, and regulates immune responses to address the root causes of prostatitis. This significantly reduces the risk of recurrence.

2. Comprehensive Anti-inflammatory Action Without Resistance

The herbal ingredients possess potent anti-inflammatory properties that effectively reduce prostate swelling and pain. Since the formula does not rely on antibiotics, it completely avoids issues like resistance or microbiome imbalance. It is suitable for both bacterial and non-bacterial prostatitis.

3. Multi-Dimensional Healing Approach

– Relieves inflammation and pain to reduce prostate swelling and urinary discomfort.

– Improves blood flow in the pelvic region, promoting prostate recovery.

– Rebuilds healthy tissue structures, addressing long-term damage caused by inflammation.

4. Natural Formula with No Side Effects

Free of hormones or synthetic chemicals, this pure herbal formula is safe for long-term use. Patients do not need to worry about side effects like liver or kidney damage commonly associated with antibiotics and synthetic drugs.

5. Improves Overall Quality of Life

In addition to resolving inflammation, the therapy addresses reproductive health issues such as ejaculatory pain and erectile dysfunction, enhancing patients’ overall quality of life — an area often overlooked in conventional treatments.

6. Holistic Regulation and Relapse Prevention

Beyond controlling localized inflammation, this therapy focuses on restoring systemic balance, boosting immunity, and enhancing the body’s natural healing capabilities. Patients experience fewer relapses and a more comprehensive recovery.

By transcending the limitations of traditional treatments, the Diuretic and Anti-inflammatory Pill offers new hope for chronic prostatitis patients. It is a natural solution that combines safety, efficacy, and holistic care.

Real Case: A 30-Year Struggle with Chronic Prostatitis Finds a Breakthrough

John, a 58-year-old man from Texas, had been battling chronic prostatitis for over 30 years. His symptoms included severe pelvic pain, difficulty and painful urinating, and painful ejaculation. Despite trying numerous treatments, including multiple courses of antibiotics, he failed to achieve lasting relief.

In his search for an effective solution, John came across the Diuretic and Anti-inflammatory Pill and decided to try it. After completing the first course of treatment, he noticed significant improvement in his pelvic pain and urinary discomfort. By the end of the second course, his overall body function began to recover, and the frequency of painful ejaculation decreased dramatically.

Following several courses of treatment, John’s symptoms improved by over 90%. A follow-up examination revealed a marked reduction in prostate inflammation, and his overall quality of life improved significantly. John shared his journey: “For the first time in decades, I feel like I have my life back. This treatment has truly changed everything for me.”

A Brighter Future for Prostate Health

The success of the Diuretic and Anti-inflammatory Pill continues to inspire hope among chronic prostatitis patients, redefining the way these conditions are managed. With its natural ingredients, multi-faceted approach, and minimal side effects, this therapy offers an effective and convenient solution for patients struggling with traditional treatments.

As global awareness of prostate health grows — fueled by stories like John’s and others — innovative, non-invasive therapies such as the Diuretic and Anti-inflammatory Pill are emerging as cornerstones for improving men’s health. For men enduring chronic prostatitis, this groundbreaking therapy offers a chance to reclaim their lives and move toward a pain-free, healthier future.

Don’t let chronic prostatitis control your life. Visit https://www.diureticspill.com/ to learn more about the Diuretic and Anti-inflammatory Pill and schedule your consultation today. Take the first step toward a healthier, pain-free future!

Media Contact
Company Name: Wuhan Dr.Lee’s TCM Clinic
Contact Person: Xiaoping Lee
Email: Send Email
Phone: 8602787105085
Address:Shop 1-3, Nan Hu Xin Cheng, Wenchang Road, Hongshan District
City: Wuhan
State: Hubei
Country: China
Website: https://www.diureticspill.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Diuretic and Anti-inflammatory Pill: A Patented Breakthrough for Managing Chronic Prostatitis Globally

Barron Prize Celebrates 25 Years of Awarding Young Heroes

““When I look at the accomplishments of these young heroes and the scope of what they have achieved during the last quarter century, I am filled with awe and appreciation,” says Prize founder and author T. A. Barron. “They work hard to make their ideals and passions a reality and are an inspiring example to us all. I am so proud of these young people who are changing the world, and I can’t wait to learn how the 2025 applicants are making a positive difference.””

Over the past twenty-five years, the Gloria Barron Prize for Young Heroes has honored hundreds of young people from across the U.S. and Canada who have addressed a wide range of important issues and made a meaningful impact on the world. The online application for the 2025 awards cycle is now open.

Established in 2001, the prestigious Barron Prize annually honors 25 outstanding young leaders ages 8 to 18 who have made a significant positive difference to people, their communities, and the planet. Fifteen top winners each receive $10,000 to support their service work or higher education. The young heroes are as diverse as their service projects. They are female and male, urban and rural, and from a wide variety of backgrounds, but they all demonstrate heroic character traits such as courage, compassion, tenacity, generosity, and a positive spirit.

Barron Prize winners have helped the hungry and the homeless, invented life-saving technologies, protected endangered species, addressed climate change, and improved literacy, among other initiatives. They have raised more than $31 million for their causes and have inspired countless people by their example. Many of the young heroes have continued their environmental and humanitarian work into adulthood.

T. A. Barron writes about fictional young heroes in his bestselling books and founded the nonprofit Barron Prize to champion real-life youth and inspire others. He named the award after his mother, Gloria Barron, who believed that every person, no matter their age or circumstance, has the power to make the world a better place.

“Nothing is more uplifting than learning about heroic people who have truly made a difference,” says T. A. Barron. “The goal of the Barron Prize is to shine the spotlight on these amazing young people so that their example will encourage others to take action.”

To learn more and apply online for 2025 visit http://www.barronprize.org/

About the Gloria Barron Prize for Young Heroes

The Barron Prize is a national award that annually honors 25 inspiring young heroes who are making a difference to people and the environment. Through the years, the Prize has earned the support of Girl Scouts of the USA, The Wilderness Society, Youth Service America, and Jane Goodall’s Roots & Shoots, among other organizations.

For information about the Barron Prize, visit www.barronprize.org

Media Contact
Company Name: CATHY CALLEGARI PUBLIC RELATIONS INC
Contact Person: Liz Ammirato
Email: Send Email
Phone: 914-299-3882
Address:159 Madison Avenue, Apt. 5J
City: New York
State: NY
Country: United States
Website: www.callprinc.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Barron Prize Celebrates 25 Years of Awarding Young Heroes